Dr. Buffington on The Use of Fusion MRI in Prostate Cancer

Philip J. Buffington, MD
Published: Monday, Nov 07, 2016


Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discusses the use of fusion magnetic resonance imaging (MRI) in prostate cancer with OncLive during the LUGPA Annual Meeting.

Fusion MRI is typically used for a second biopsy, in patients with prostate cancer who are on active surveillance, or patients who have had a negative biopsy in the past, but their PSA is still rising, Buffington says. The MRI helps target an area that may have been missed on a prior biopsy.

The images from the MRI are then fused with the images on the ultrasound, which allows urologists to better target and bioposy the area.

Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discusses the use of fusion magnetic resonance imaging (MRI) in prostate cancer with OncLive during the LUGPA Annual Meeting.

Fusion MRI is typically used for a second biopsy, in patients with prostate cancer who are on active surveillance, or patients who have had a negative biopsy in the past, but their PSA is still rising, Buffington says. The MRI helps target an area that may have been missed on a prior biopsy.

The images from the MRI are then fused with the images on the ultrasound, which allows urologists to better target and bioposy the area.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x